PRDX1-IN-1 is a selective inhibtor of PRDX1 with an IC50 value of 0.164 μM. PRDX1-IN-1 can be used in researches related to cancer.PRDX1-IN-1 promots intracellular ROS accumulation, and inhibits the proliferation, invasion and migration of cancer cells besides inducing apoptosis. PRDX1-IN-1 could be used in cancer research.
PRDX1-IN-1 inhibites the proliferation activities of the human lung cancer cells A549, lung cancer cell lines (LTEP-a-2 and H1975), human breast cancer cell line (MDA-MB-231), human hepatoma cell line (SK-Hep-1) with the IC50 values of 1.92 μM, 2.93 μM, 1.99 μM, 2.67 μM, 2.42μM, respectively[1].PRDX1-IN-1 (compound 7e)(2 μM or 4 μM, 24 h) promotes intracellular ROS accumulation, and inhibits the invasion and migration of human lung cancer cells A549[1].PRDX1-IN-1 (2 μM or 4 μM, 24 h) induces the apoptosis of A549 cells[1].PRDX1-IN-1 (2 μM or 4 μM, 6 h) suppresses the key signaling pathways (AKT and ERK) and promotes the expression of apoptosis-related proteins (cleaved caspase-3/8 and cleaved PARP) in A549 cells[1].
PRDX1-IN-1 (0.5 or 1 mg/kg, intraperitoneal(i.p.), 19 days, every day) inhibited tumor growth in a mouse model of lung cancer[1].
References:
[1]. Ying Bai, et al. Development of novel celastrol-ligustrazine brids as potent peroxiredoxin 1 inhibitors against lung cancer. Eur J Med Chem. 2023, 259, 115656.